

***Fiscal Year 2021 Duchenne Muscular Dystrophy Research Program (DMDRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Idea Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>W81XWH-21-DMDRP-IDA</p>	<p><b><i>Established Investigators:</i></b> Independent investigators at or above the level of Assistant Professor (or equivalent); <b><i>or</i></b></p> <p><b><i>New Investigators:</i></b> Investigators that meet the following criteria by the application submission deadline date:</p> <ul style="list-style-type: none"> <li>• Have not previously received a DMDRP Idea Development Award</li> <li>• Are <b>within 10 years</b> of first faculty appointment (or equivalent)</li> </ul>	<ul style="list-style-type: none"> <li>• Supports the development of innovative, high-impact ideas that advance the understanding of Duchenne muscular dystrophy (DMD) and ultimately lead to improved outcomes.</li> <li>• Must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Eligible therapeutic strategies include: gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies. <b><i>Therapies that will be efficacious across the life-span, particularly in adolescents and adults are encouraged.</i></b></li> <li>• <b>Preliminary data required.</b></li> <li>• Clinical trials or applications including a clinical trial aim are <b><i>not allowed.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$350,000</b> in direct costs (plus indirect costs).</li> <li>• Maximum period of performance is <b>2 years</b>.</li> </ul>	<p><b>Pre-Application:</b> August 11, 2021 5:00 p.m. Eastern time</p> <p><b><i>Preproposal is required; application submission is by invitation only.</i></b></p> <p><b>Application:</b> December 1, 2021 11:59 p.m. Eastern time</p>
<p><b>Translational Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>W81XWH-21-DMDRP-TRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports translational studies that have moved beyond the realm of basic research and have the potential to result in a near-term impact in clinical research or the clinic.</li> <li>• Research projects investigating therapies that will be efficacious across the life-span, particularly in adolescents and adults are strongly encouraged.</li> <li>• <b>Preliminary data required.</b></li> <li>• <b>Clinical trials are allowed</b></li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$1,300,000</b> in direct costs (plus indirect costs).</li> <li>• Maximum period of performance is <b>3 years</b></li> </ul>	<p><b>Pre-Application:</b> August 11, 2021 5:00 p.m. Eastern time</p> <p><b><i>Preproposal is required; application submission is by invitation only.</i></b></p> <p><b>Application:</b> December 1, 2021 11:59 p.m. Eastern time</p>